Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

1. Hereditary haemorrhagic telangiectasia.Nature reviews. Disease primers · 2025
   Review
2. Mutations causing premature termination codons discriminate and generate cellular and clinical variability in HHT.Blood · 2024
   Article
3. Pharmacogenomic Considerations for Anticoagulant Prescription in Patients with Hereditary Haemorrhagic Telangiectasia.Journal of clinical medicine · 2023
   Article
4. Unsupervised machine learning algorithms identify expected haemorrhage relationships but define unexplained coagulation profiles mapping to thrombotic phenotypes in hereditary haemorrhagic telangiectasia.EJHaem · 2023
   Article
5. Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation.Blood advances · 2022
   Article
6. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations.BMJ case reports · 2021
   Article
7. Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia.Blood · 2020
   Article
8. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.Blood · 2019
   Article
9. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.Orphanet journal of rare diseases · 2019
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as